J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows

The much-anticipated CAR-T showdown between Bristol Myers Squibb and the alliance of Johnson & Johnson and Legend Biotech in the early treatment of multiple myeloma has arrived sooner than expected—courtesy of a data leak.